In MC-38 study, mean percent tumor growth inhibition (TGI) of combination demonstrated 65% tumor growth inhibition, versus 39% and 33% for anti-PD-1 and CBT-101 respectively. This evidence concerns the gene PDCD1 and neoplasm.